目的 探讨晕痛定胶囊联合苯噻啶片治疗偏头痛的临床疗效。方法 选取2017年5月-2018年5月在西安市北方医院诊治的偏头痛患者84例，根据用药的差别分为对照组（42例）和治疗组（42例）。对照组口服苯噻啶片，第1~3天每晚服0.5 mg，第4~6天每天中、晚各服0.5 mg，第7天开始每天早、中、晚各服0.5 mg，如病情基本控制，可酌情每周递减0.5 mg。治疗组在对照组基础上口服晕痛定胶囊，1.2 g/次，3次/d。两组均治疗6周。观察两组患者临床疗效，同时比较治疗前后两组患者临床症状改善情况、血清学指标水平和血管活性物质水平情况。结果 治疗后，对照组临床有效率为80.95%，显著低于治疗组的97.62%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者头痛发作次数、头痛发作持续时间均明显降低（P<0.05），且治疗组患者临床症状明显好于对照组（P<0.05）。治疗后，两组血清超敏C反应蛋白（hs-CRP）、白细胞介素-1β（IL-1β）、IL-6、同型半胱氨酸（Hcy）、内皮素-1（ET-1）、血栓素B2（TXB2）水平均降低（P<0.05），多巴胺（DA）、5-羟色胺（5-HT）和一氧化氮（NO）水平均显著升高（P<0.05），且治疗组患者上述指标水平明显好于对照组（P<0.05）。结论 晕痛定胶囊联合苯噻啶片治疗偏头痛可有效改善患者临床症状，降低机体炎症反应，改善机体血管活性物质水平，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Yuntongding Capsules combined with pizotifen in treatment of migraine. Methods Patients (84 cases) with migraine in Xi'an North Hospital from May 2017 to May 2018 were divided into control (42 cases) and treatment (42 cases) groups based on different treatments. Patients in the control group were po administered with Sumatriptan Succinate Tablets, 0.5 mg for every night of 1-3 d, 0.5 mg for every noon and night of 4-6 d, then 0.5 mg/time, three times daily from the 7th day, 0.5 mg/week was decreased as appropriate when basic disease controlled. Patients in the treatment group were po administered with Yuntongding Capsules on the basis of the control group, 1.2 g/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy was evaluated, and the improvement of clinical symptoms, and the serological indexes levels, the vasoactive substances levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 80.95%, which was significantly lower than 97.62% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the frequency of migraine attacks and duration of headache attack in two groups was significantly decreased (P < 0.05), and which in the treatment group was significantly lower than that in the control group (P < 0.05). After treatment, the serum hs-CRP, IL-1β, IL-6, Hcy ET-1 and TXB2 levels in two groups were significantly decreased (P < 0.05), but the serum DA, 5-HT and NO levels were significantly increased (P < 0.05), and these indexes levels in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion Yuntongding Capsules combined with pizotifen in treatment of migraine can effectively improve the clinical symptoms, reduce inflammation, improve the level of vasoactive substances, which has a certain clinical application value.